A live attenuated SARS-CoV-2 vaccine constructed by dual inactivation of NSP16 and ORF3a.

ABSTRACT:

Background

Live attenuated vaccines against SARS-CoV-2 activate all phases of host immunity resembling a natural infection and they block viral transmission more efficiently than existing vaccines in human use. In our prior work, we characterised an attenuated SARS-CoV-2 variant, designated d16, which harbours a D130A mutation in the NSP16 protein, inactivating its 2'-O-methyltransferase function. The d16 variant has demonstrated an ability to induce both mucosal and sterilising immunity in animal models. However, further investigation is required to identify any additional modifications to d16 that could mitigate concerns regarding potential virulence reversion and the suboptimal regulation of the proinflammatory response.

Methods

Mutations were introduced into molecular cl

SUBMITTER: Ye ZW 

PROVIDER: S-EPMC11985078 | biostudies-literature | 2025 Apr

REPOSITORIES: biostudies-literature